PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk
Recruiting now · Phase 2
Conditions studied: Renal Cell Carcinoma (RCC), Metastatic Renal Cell Carcinoma (mRCC)
In brief
This phase 2 trial aims to test the feasibility and efficiency of PET/CT-directed treatment interruption strategy in metastatic renal cell carcinoma patients with IMDC favorable/intermediate risk who achieve complete (CMR) or partial metabolic response (PMR) after ≥12 months of first-line PD-1/PD-L1 Immune checkpoint inhibitor (ICI)+ VEGFR-tyrosine kinase inhibitor (TKI) therapy. It helps figure out whether PET/CT can safely direct treatment pause as well as explores a new individualized treatment option based on metabolic imaging for RCC patients.
Key facts
- Study ID
- NCT07175480
- Run by
- Jinling Hospital, China
- People needed
- 30
- Starts
- 2025-01-24
- Expected to finish
- 2030-08-01
- Last updated by the study team
- 2025-09-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China — Nanjing, Jiangsu, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.